Search results
Results from the WOW.Com Content Network
Cilengitide (EMD 121974) is a molecule designed and synthesized at the Technical University Munich in collaboration with Merck KGaA in Darmstadt.It is based on the cyclic peptide cyclo(-RGDfV-), which is selective for α v integrins, which are important in angiogenesis (forming new blood vessels), and other aspects of tumor biology.
Dostarlimab was approved for the treatment of endometrial cancer in both the United States and the European Union in April 2021. [5] [6] [11] [8] [12] Based on the Garnet trial, dostarlimab gained accelerated approval from the US Food and Drug Administration (FDA) in April 2021, [6] and full approval in February 2023. [7]
Another remaining question surrounding CDK inhibitors as a therapy is if certain cancers will evade or be resistant to treatment. One study showed that 20% of the patients being treated for metastatic ER+ HER2-breast cancer did not respond at all to treatment with a CDK4/6 inhibitor due to preexisting mutations allowing the cancer cells to continue proliferating despite treatment with the drug ...
Zilucoplan is a cyclic peptide that binds to the protein complement component 5 (C5) and inhibits its cleavage into C5a and C5b. [11] Zilucoplan was approved for medical use in the United States in October 2023, [6] [12] in the European Union in December 2023, [7] and in Australia in July 2024. [1]
The U.S. Food and Drug Administration (FDA) approved Seasonale in the United States on September 5, 2003. [26] Barr Pharmaceuticals, its manufacturer, claimed at the time of Seasonale's approval that it would cost one dollar per pill. [25] Health Canada approved Seasonale in July 2007, and Paladin Labs began distributing it in Canada on January ...
The medication is a peptide and acts by activating the melanocortin receptors. [1] [5] Bremelanotide was approved for medical use in the United States in 2019. [2] [6] It was developed by Palatin Technologies. [7] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [8]
Cetrorelix (INN Tooltip International Nonproprietary Name, BAN Tooltip British Approved Name), or cetrorelix acetate (USAN Tooltip United States Adopted Name, JAN Tooltip Japanese Accepted Name), sold under the brand name Cetrotide, is an injectable gonadotropin-releasing hormone (GnRH) antagonist.
Bortezomib causes a rapid and dramatic change in the levels of intracellular peptides that are produced by the proteasome. [17] Some intracellular peptides have been shown to be biologically active, and so the effect of bortezomib on the levels of intracellular peptides may contribute to the biological and/or side effects of the drug.